Skip to main content
. Author manuscript; available in PMC: 2014 Aug 14.
Published in final edited form as: Cancer. 2012 May 8;118(22):5614–5622. doi: 10.1002/cncr.27593

Figure 3.

Figure 3

Figure 3

Panel A: Distribution of severity of numbness or tingling in hands, for 353 NSABP C-07 patients participating in the Long-Term Survivors, LTS-01, long-term assessment of neurotoxicity; P-value compares distributions by treatment across the 5 levels of severity; FULV, fluorouracil and leucovorin; FLOX, FULV plus oxaliplatin.

Panel B: Distribution of severity of numbness or tingling in feet, for 353 NSABP C-07 patients participating in the Long-Term Survivors, LTS-01, long-term assessment of neurotoxicity; P-value compares distributions by treatment across the 5 levels of severity; FULV, fluorouracil and leucovorin; FLOX, FULV plus oxaliplatin.